Personalized medicine has long been a buzzword in psychiatry, and in 2026, the conversation is heating up around pharmacogenomics (PGx) and its role in treating schizophrenia. Polygenic risk scores—essentially a tally of genetic risk factors weighted by their impact—are now being studied as potential predictors of how patients respond to antipsychotic medications. But despite the excitement, these genetic markers are not yet ready for primetime in psychiatric clinics.
Genetics and Antipsychotic Response: Where Are We Now?
Recent research, including a review by Zai CC and colleagues, points to the potential for polygenic risk scores to inform treatment. The idea is simple but powerful: by understanding a patient’s unique genetic makeup, doctors could one day predict which antipsychotic will work best and which might cause problematic side effects. However, as of August 2026, these PGx markers haven’t been validated enough to guide everyday clinical decisions for schizophrenia.
A real-world illustration of this gap was highlighted in the American Journal of Psychiatry, where a 25-year-old man with treatment-resistant schizophrenia improved rapidly on clozapine—even though his PGx test actually advised against using the drug. This kind of case underscores why clinicians are still wary of relying solely on genetic tests when choosing antipsychotics.
What’s Next? Ongoing Trials and Future Directions
The research community isn’t standing still. Several randomized controlled trials (like NCT02573168 and NCT02566057) are currently underway to better evaluate the clinical utility of pharmacogenetic testing for antipsychotic response. These studies aim to answer critical questions about whether single or combined PGx tests can really improve treatment outcomes for patients with schizophrenia. Experts hope that as more genetic variants are identified and combined with non-genetic factors, truly actionable markers will emerge.
For now, the consensus is clear: while the science is promising and moving fast, pharmacogenomics in schizophrenia treatment is not yet ready for widespread clinical adoption. But with ongoing trials and rapid advances in the genomic field, the coming years could bring the clarity clinicians and patients have been waiting for.
